CUBIST PHARMACEUTICALS
Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic... developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.
CUBIST PHARMACEUTICALS
Industry:
Biotechnology Medical
Founded:
1992-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.cubist.com
Total Employee:
5001+
Status:
Closed
Contact:
7812401261
Technology used in webpage:
SPF Microsoft Exchange Online Microsoft Azure DNS AWS Global Accelerator Rackspace Cisco Ironport Cloud Pubmatic Internap ATT DNS Rackspace Cloud Servers
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2013-07-30 | Trius Therapeutics | Trius Therapeutics acquired by Cubist Pharmaceuticals | 704 M USD |
2013-07-30 | Optimer Pharmaceuticals | Optimer Pharmaceuticals acquired by Cubist Pharmaceuticals | 535 M USD |
2011-12-12 | Adolor | Adolor acquired by Cubist Pharmaceuticals | N/A |
2009-12-14 | Calixa Therapeutics | Calixa Therapeutics acquired by Cubist Pharmaceuticals | N/A |
2007-12-24 | Illumigen Biosciences | Illumigen Biosciences acquired by Cubist Pharmaceuticals | N/A |
Official Site Inspections
http://www.cubist.com
- Host name: 155.91.16.177
- IP address: 155.91.16.177
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago